3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
5
Phase 1/2
2
Phase NA
1
Status
Recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Conditions
Carcinoma, Non-Small-Cell Lung
255
Breast Neoplasms
172
Neoplasms
167
Colorectal Neoplasms
154
Neoplasm Metastasis
127
Melanoma
119
Recurrence
116
Prostatic Neoplasms
116
Leukemia, Myeloid, Acute
115
Pancreatic Neoplasms
113
Ovarian Neoplasms
110
Multiple Myeloma
103
Lung Neoplasms
95
Stomach Neoplasms
89
Squamous Cell Carcinoma of Head and Neck
82
Triple Negative Breast Neoplasms
81
Glioblastoma
81
Lymphoma
76
Lymphoma, Non-Hodgkin
75
Lymphoma, Large B-Cell, Diffuse
64
Carcinoma, Renal Cell
64
Precursor Cell Lymphoblastic Leukemia-Lymphoma
62
Advanced Solid Tumor
59
Endometrial Neoplasms
58
Carcinoma, Hepatocellular
57
Small Cell Lung Carcinoma
54
Sarcoma
52
Uterine Cervical Neoplasms
51
Myelodysplastic Syndromes
51
Advanced Solid Tumors
49
Interventions
fludarabine
1
Cyclophosphamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 1/2
×
Simpson-Golabi-Behmel syndrome
×
1 year
×
Clear all
NCT06795022
2026-04-06
RHEA-1
AstraZeneca
Phase 1/2
Recruiting
304 enrolled
NCT07500220
2026-03-30
DUET-HCC
Beijing Biotech
Phase 1/2
Recruiting
30 enrolled